CJC-1295 vs Sermorelin

How they're alike

Both peptides are synthetic analogs of the same parent molecule: the N-terminal 29-residue fragment of human growth hormone-releasing hormone, the shortest portion of native GHRH that retains full activity at the GHRH receptor (Ling 1984). Their backbones are identical over the shared 29 amino acids — a BLOSUM62 local alignment returns 100% identity across that stretch — and both act as agonists at the GHRH receptor on anterior-pituitary somatotrophs, engaging the same cAMP/PKA cascade that drives growth-hormone gene transcription and pulsatile GH secretion. Because the stimulus is upstream of the pituitary rather than substitutive, downstream pulsatility and somatostatin-mediated negative feedback remain operative for both compounds; IGF-1 elevation is the shared distal pharmacology (Prakash 1999; Jetté 2005). A review of growth-hormone secretagogues in hypogonadal males groups Sermorelin and CJC-1295 together as GHRH-class secretagogues distinguished from the ghrelin-receptor (GHS-R) family (Sinha 2020).

How they differ

The differences are entirely on the pharmacokinetic side rather than the receptor side. Sermorelin is the native GHRH(1-29) sequence with a C-terminal amide; it is rapidly degraded by DPP-IV and other peptidases and clears with a plasma half-life on the order of minutes by the IV route, so each subcutaneous dose produces a single transient GH pulse before the peptide is gone (Prakash 1999; Walker 2006). CJC-1295 is the same backbone re-engineered for endurance: four amino-acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) confer resistance to DPP-IV cleavage, and in the DAC variant a maleimidopropionic-acid linker at the C-terminal lysine covalently binds Cys-34 on circulating serum albumin after injection. Jetté and colleagues (2005) characterized this albumin bioconjugation in rats and identified CJC-1295 as a long-lasting GRF analog; subsequent human work confirmed an active half-life of approximately 6–8 days, so a single dose maintains continuous GHRH-receptor engagement over days rather than producing a discrete pulse.

That kinetic split changes how the GH curve looks downstream. Ionescu and Frohman (2006) showed that pulsatile GH secretion persists during continuous CJC-1295 stimulation — the intrinsic pituitary rhythm and the independent ghrelin/GHS-R axis keep producing pulses on top of the sustained CJC-1295 signal — whereas a Sermorelin dose itself is the pulse. The regulatory and evidentiary landscapes diverge in parallel. Sermorelin has a formal FDA-approval history (Geref, NDA 19-863 in 1990 for GH-deficiency diagnostics and NDA 20-443 in 1997 for pediatric idiopathic GHD), commercial production was discontinued by EMD Serono in 2008, and the compound now reaches patients only through state-licensed compounding pharmacies for off-label adult use; a clinical-interventions review proposed adult-onset GH insufficiency as a candidate indication but did not provide a controlled adult efficacy trial (Walker 2006). CJC-1295 never achieved any major regulatory approval: ConjuChem advanced the DAC form through Phase I in healthy adults and into Phase II in HIV-associated lipodystrophy, the Phase II program was discontinued after a patient death (adjudicated as unrelated by the attending physician but never independently published), and the compound has since circulated only as a research-chemical and compounding-pharmacy peptide.

Head-to-head clinical evidence

No direct head-to-head clinical trial comparing Sermorelin and CJC-1295 is present in the dossier's union of cited literature, and no PubMed candidates mentioning both peptides in the title were identified during dossier construction. The two compounds were developed in different eras and for different intended uses — Sermorelin as a 1990s pediatric GH-deficiency therapeutic and pituitary-reserve diagnostic, CJC-1295 as an early-2000s long-acting analog aimed at HIV-associated lipodystrophy — and their published human evidence bases do not overlap on a shared endpoint, population, or sponsor. The closest indirect comparisons come from review and characterization papers that discuss the GHRH-analog class as a whole: Jetté and colleagues (2005) explicitly framed CJC-1295 as a long-lasting alternative to short-half-life GRF analogs of which Sermorelin is the canonical example, and an orthopaedic-applications review (Rahman 2026) groups GHRH-class secretagogues together as a single therapeutic family without trial-level head-to-head data. Studies of native GHRH-40 across IV, SC, and intranasal routes (Gelato 1985) establish the pharmacokinetic baseline both analogs are engineered against but do not compare the analogs directly.

Safety profile comparison

The shared adverse-event profile is dominated by the pharmacology of GHRH-receptor activation: injection-site reactions, transient facial flushing, occasional mild headache, and dizziness or altered taste — the Sermorelin entries arising from the Geref label-era safety dataset and the Walker (2006) review, the CJC-1295 entries arising from the Teichman Phase I program (cited in the CJC-1295 dossier readme). Beyond that overlap, the two profiles differ along the same axis as their pharmacokinetics. Sermorelin's safety record is the more mature — supported by a pediatric FDA-approval-era dataset and the 2013 Federal Register determination that the 2008 commercial withdrawal was not for reasons of safety or effectiveness — but it is pediatric and shorter-term, and long-duration safety in healthy or aging adults at compounding-era exposures has not been characterized in a controlled trial (Walker 2006; Prakash 1999). CJC-1295's longer-acting DAC form raises a distinct, mechanism-level concern: a single dose produces multi-day sustained IGF-1 elevation rather than a transient pulse, and the cancer-promotion concern shared with all GH-raising compounds is not resolved by the published evidence base. Phase II program discontinuation after a patient death, with no peer-reviewed adjudication of the safety signal, sits unresolved at the boundary of the CJC-1295 safety record. Neither compound has long-term (>12 month) human safety data in healthy adults in the dossier's literature.

Indication overview

Sermorelin's only ever-approved indications are historical: pituitary GH-reserve diagnostics (Geref Diagnostic, NDA 19-863, 1990) and pediatric idiopathic growth hormone deficiency (Geref, NDA 20-443, 1997), both withdrawn from the US market in 2008 with NDAs formally withdrawn in 2009 (Prakash 1999; Walker 2006). It is not currently approved in the US, EU, UK, Canada, or Australia, and is available in the US only via state-licensed compounding-pharmacy prescription for off-label adult use. Chang and colleagues (2021) discuss Sermorelin as a candidate drug for recurrent glioma — an exploratory indication, not an approval. CJC-1295 has no approved indication in any major regulatory jurisdiction; its development history extends only to a completed Phase I program in healthy adults (Teichman 2006, cited in the CJC-1295 dossier readme) and a discontinued Phase II program in HIV-associated lipodystrophy (Jetté 2005; Ionescu 2006). Both compounds are listed on the WADA Prohibited List under class S2 (peptide hormones, growth factors, related substances and mimetics) at all times, regardless of historical approval status. These statements are factual descriptions of regulatory state and published indication; they are not treatment recommendations, and the choice of which (if either) is appropriate for any individual is outside the scope of a comparison page.